GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01106599
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01090960
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT01087151
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01075464
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01068977
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT01059630
- Locations
- 🇺🇸
South Texas Inst of Cancer, Corpus Christi, Texas, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00999128
- Locations
- 🇺🇸
Genentech Trial Information Support, South San Francisco, California, United States
A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00997919
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT00996892
A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00991718
© Copyright 2024. All Rights Reserved by MedPath